Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00003845

Trial Description

start of 1:1-Block title

Title

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

RATIONALE: Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Midostaurin may help daunorubicin and cytarabine work better by
making cancer cells more sensitive to the drugs. Midostaurin also may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether combination chemotherapy is more effective with or without midostaurin in treating
acute myeloid leukemia.

PURPOSE: This randomized phase III trial is studying giving daunorubicin and cytarabine with
or without midostaurin followed by high-dose cytarabine and midostaurin to see how well it
works in treating patients with newly diagnosed acute myeloid leukemia.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

OBJECTIVES:

Primary

- To determine if the addition of midostaurin (vs placebo) to induction therapy
comprising daunorubicin hydrochloride and cytarabine, consolidation therapy comprising
high-dose cytarabine, and continuation therapy improves overall survival of patients
with newly diagnosed acute myeloid leukemia with FLT3-internal tandem duplication (ITD)
or FLT-3 tyrosine kinase domain (TKD) mutations.

Secondary

- To compare the complete response rate in patients treated with these regimens.

- To compare the event-free survival (EFS) of patients treated with these regimens.

- To compare the disease-free survival (DFS) of patients treated with these regimens.

- To compare the DFS rate of these patients after 1 year of continuation therapy.

- To compare the overall survival (OS) in the two groups using an analysis in which
patients who receive a stem cell transplant are censored at the time of transplant.

- To assess the toxicity of these regimens in these patients.

- To describe the interaction between treatment outcome and pretreatment characteristics
such as age, performance status, white blood cell count, morphology, cytogenetics, and
molecular and pharmacodynamic features.

- To assess the population pharmacokinetics (PK) of midostaurin and its two major
metabolites, CGP52421 and CGP62221.

- To explore the potential association between PK exposure and FLT3 status, overall
survival, EFS, and clinical response in patients treated with these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to FLT3 mutation
status (internal tandem duplication [ITD] allelic ratio < 0.7 vs ITD allelic ratio ≥ 0.7 vs
tandem kinase domain [TKD]).

- Remission induction therapy: Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin
hydrochloride IV on days 1-3. Patients also receive oral midostaurin twice daily
on days 8-21.

- Arm II: Patients receive cytarabine and daunorubicin hydrochloride as in arm I.
Patients also receive oral placebo twice daily on days 8-21.

Patients undergo bone marrow aspiration on day 21 to assess response. If residual leukemia
is present on day 21 or upon subsequent bone marrow aspiration, patients proceed to second
remission induction therapy.

- Second remission induction therapy: Patients receive a second course of remission
induction therapy according to their initial randomization. Treatment begins on or
shortly after day 24 (i.e., at least 3 days after completing prior midostaurin or
placebo therapy). Within 1 week after hematologic recovery and 60 days after initiating
protocol treatment, patients undergo assessment of response. Patients with residual
acute myeloid leukemia are removed from study. Patients with complete response (CR)
proceed to consolidation therapy.

- Remission consolidation therapy: Beginning within 2 weeks after hematologic recovery
and at least 4 weeks after initiation of the last course of induction therapy, patients
with CR receive high-dose cytarabine (HiDAC) IV over 3 hours every 12 hours on days 1,
3, and 5 and oral midostaurin or placebo therapy according to the initial
randomization. Treatment repeats every 4 weeks for up to 4 courses in the absence of
disease progression or unacceptable toxicity.

- Continuation therapy: Patients who continue in CR after four courses of HiDAC
consolidation therapy receive continuation therapy with midostaurin or placebo alone
according to their initial randomization. Patients who are unable to complete four
courses of HiDAC consolidation therapy because of toxicity may receive continuation
therapy at the discretion of the principal investigator. Beginning at least 14 days
after the last dose of consolidation midostaurin or placebo and after recovery from
hematologic and other significant acute toxicity, patients receive oral midostaurin or
placebo twice daily on days 1-28. Treatment repeats every 28 days for up to 12 months
or until relapse.

Patients may also enroll on optional pharmacokinetics study CALGB-60706.

After completion of study therapy, patients are followed periodically for up to 10 years.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003845
  •   2012/05/02
  •   2008/04/01
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2006-006852-37 
  •   NCT00651261  (ClinicalTrials.gov)
  •   CDR0000590404  (Cancer and Leukemia Group B)
  •   CALGB-10603 
  •   EUDRACT-2006-006852-37 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Leukemia
  •   C92.0 -  Acute myeloid leukaemia
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: cytarabine
  •   Drug: daunorubicin hydrochloride
  •   Drug: midostaurin
  •   Other: placebo
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Overall survival (OS); time frame: Duration of study (Up to 10 years)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- OS where patients who receive a stem cell transplant are censored at the time of the transplant; time frame: Duration of study (Up to 10 years)
- Complete response rate in the remission induction stage of the study; time frame: Duration of study (Up to 10 years)
- Event- free survival; time frame: Duration of study (Up to 10 years)
- Disease-free survival (DFS); time frame: Duration of study (Up to 10 years)
- DFS rate one year after completing the planned continuation phase; time frame: 30 months

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Canada
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2008/04/30
  •   714
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   59   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

DISEASE CHARACTERISTICS:

- Unequivocal diagnosis of acute myeloid leukemia (AML) meeting the following criteria:

- More than 20% blasts present in the bone marrow, as defined by WHO
classification

- Documented FLT3 mutation (i.e., internal tandem duplication [ITD] or point
mutation), determined by analysis in a protocol-designated FLT3 screening
laboratory

- No acute promyelocytic leukemia (M3)

- Patients with antecedent myelodysplasia (MDS) allowed, provided they received no
prior cytotoxic (including azacytidine or decitabine) therapy for MDS

- No therapy-related AML after prior radiotherapy or chemotherapy for another disorder
or cancer

- Patients with neurologic symptoms suggestive of CNS leukemia may undergo a lumbar
puncture

- Patients with a positive CSF for AML blasts are not eligible

PATIENT CHARACTERISTICS:

- No symptomatic congestive heart failure

- Total bilirubin < 2.5 times upper limit of normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use 2 methods of effective contraception during and for 12
weeks after completion of study therapy

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior therapy for leukemia or myelodysplasia, except for the following:

- Emergency leukapheresis

- Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 5 days

- Cranial radiotherapy for CNS leukostasis (one dose only)

- Growth factor or cytokine support

- No concurrent hormones or other chemotherapy, except steroids given for
hypersensitivity or transfusion reactions or hormones for non-disease-related
conditions (e.g., insulin for diabetes)

- No concurrent apprepitant

- No concurrent enrollment on another clinical trial with investigational agents

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

[---]*

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Cancer and Leukemia Group B
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Dana-Farber Cancer Institute
    • Richard M. Stone, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Dana-Farber Cancer Institute
    • Richard M. Stone, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   91
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.